NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.

Tracy T BatchelorMinhee WonArnab ChakravartiCostas G HadjipanayisWenyin ShiLynn S AshbyVolker W StieberH Ian RobinsHeidi J GrayAlfredo VoloschinKristen O RileyClifford G RobinsonUshaSree ChamarthyYoung KwokTerrence P CesconAnand K SharmaRekha ChaudharyMei-Yin PolleyMinesh P Mehta

Published in: Neuro-oncology advances (2023)

This study met its primary endpoint of prolongation of 6-month PFS with cediranib in combination with radiation and temozolomide versus placebo in combination with radiation and temozolomide. There was no difference in overall survival between the 2 arms.

Keyphrases

double blind
phase ii
placebo controlled
newly diagnosed
clinical trial
phase iii
open label
study protocol
radiation induced
rectal cancer
tyrosine kinase
randomized controlled trial
drug induced